Example Image¶à²ÊÍø

ÆóÒµ¶¯Ì¬
¾Û½¹Ö×ÁöÔçɸм¼Êõ ¶à²ÊÍøÉúÎïÁÁÏà2024µÂ¹úMEDICA
2024-11-19
ȪԴ£º¶à²ÊÍøÉúÎï

2024Äê11ÔÂ11-14ÈÕ£¬ £¬£¬£¬£¬£¬È«Çò¹æÄ£×î´ó¡¢Ó°ÏìÁ¦×î¹ãµÄÒ½ÁÆÆ÷еչ»áÖ®Ò»MEDICA£¬ £¬£¬£¬£¬£¬Ôڵ¹ú¶ÅÈû¶û¶à·òÊ¢·Å×ÝÐС£¡£¡£¡£¡£×÷ΪÖ×ÁöÔçɸºÍÒºÌå»î¼ìÁìÓòµÄÁì¾üÆóÒµ£¬ £¬£¬£¬£¬£¬¶à²ÊÍøÉúÎSinglera Genomics£©Ð¯¶àÏîÁ¢Òì²úÆ·ºÍ¼¼Êõ¾ªÑÞÁÁÏ࣬ £¬£¬£¬£¬£¬ÓëÀ´×ÔÊÀ½ç¸÷µØµÄÏàÖúͬ°éÉîÈë̽ÌÖÖ×ÁöÔçɸÔçÕïÁìÓòµÄÇ°ÑØÏ£ÍûÓëÏàÖú»úÔµ¡£¡£¡£¡£¡£

 

¶à²ÊÍø(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø

 

ÔÚÕ¹»áÉÏ£¬ £¬£¬£¬£¬£¬±¸ÊܹØ×¢µÄÃ÷ÐDzúÆ·ÊÇColonAiQ®£¨ÑªÒº³¦°©¶à»ùÒò¼×»ù»¯Ó«¹âPCRÊÔ¼ÁºÐ£©¡£¡£¡£¡£¡£Õâ¿î²úÆ·²»µ«Äܹ»ÊµÏÖ½áÖ±³¦°©µÄÔçÕ £¬£¬£¬£¬£¬»¹¿ÉÓÃÓÚ³¦°©¸ùÖÎÊõºó¸´·¢µÄÕ¹ÍûÓë¼à²â¡£¡£¡£¡£¡£Ïà±È¹Å°åµÄÓ°Ïñѧ¡¢ÂѰ××éѧ£¬ £¬£¬£¬£¬£¬ColonAiQ®Ê¹ÓÃÑ­»·Ö×ÁöDNA£¨ctDNA£©¾ßÓÐʵʱ¡¢ÎÞ´´¡¢±ã½ÝµÈÓÅÊÆ¡£¡£¡£¡£¡£»£»£»£»¹¿ÉÓÃ×÷I-IIIÆÚ½áÖ±³¦°©Êõºó¸´·¢Î£º¦Éý¸ßµÄ·Ö×Ó±ê¼ÇÎï[1]¡£¡£¡£¡£¡£

 

±ðµÄ£¬ £¬£¬£¬£¬£¬ÎÒÃÇ»¹´øÀ´ÁËÕë¶Ô¸Îϸ°û°©µÄ¸¨ÖúÕï¶ÏºÍ»¼ÕßÔ¤ºóÆÀ¹ÀµÄ¼×»ù»¯Ð²úÆ·——HepaAiQ®¡£¡£¡£¡£¡£¸Ã²úÆ·ÔÚHCC£¨Hepatocellular Carcinoma£©µÄ¸¨ÖúÕï¶ÏÖÐÌåÏÖ¾«²Ê£¬ £¬£¬£¬£¬£¬ÆäÌØÒìÐÔºÍѸËٶȾùÏÔÖø¸ßÓڹŰåµÄAFPºÍDCPÖ¸±ê£¬ £¬£¬£¬£¬£¬ÓÐÖúÓÚ¸üÔçµØ·¢Ã÷HCC»¼ÕߵIJ¡Ç飬 £¬£¬£¬£¬£¬²¢ÎªÔ¤·ÀÐÔɸ²éºÍÁÆÐ§¼à¿ØÌṩ¸ü±ã½ÝµÄ¼à²â¹¤¾ß[2]¡£¡£¡£¡£¡£

 

³ýÁ˲úÆ·³öº£Ä£Ê½£¬ £¬£¬£¬£¬£¬¶à²ÊÍøÉúÎﻹÓëÀ´×ÔÅ·Ö޺ͱ±ÃÀ¡¢À­ÃÀµÄDZÔÚÏàÖúͬ°éÉîÈë̽ÌÖÁËÁ¢Òì¼¼Êõ³öº£µÄÏàÖúģʽ£¬ £¬£¬£¬£¬£¬²¢¸æ¿¢ÆÕ±é¹²Ê¶¡£¡£¡£¡£¡£ÎÒÃǺÜÊÇ×ÔºÀµØ½éÉÜÁËÕë¶ÔÒÈÏÙ°©£¨PDAC£©µÄÔçÆÚɸ²é¼¼Êõ——PDACatch™£¬ £¬£¬£¬£¬£¬¿É»ùÓÚ¶þ´ú²âÐòƽ̨ÉÏ×ÊÖú¸ßΣº¦ÒÈÏÙ°©»¼Õ߸üÔçµØ·¢Ã÷Σº¦²¢ÊµÊ±¸ÉÔ¤¡£¡£¡£¡£¡£Õâ¿î²úÆ·ÔøÈÙ»ñÃÀ¹úFDAµÄÍ»ÆÆÐÔÆ÷еÈ϶¨£¨Breakthrough Devices Designation£©¡£¡£¡£¡£¡£

 

¶à²ÊÍø(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø

 

¶à²ÊÍøÉúÎïÔÚMEDICAÕ¹»áÉϵľ«²ÊÌåÏÖ£¬ £¬£¬£¬£¬£¬ÕÃÏÔÁËÆóҵǿʢµÄÆ·ÅÆÕкôÁ¦ÒÔ¼°ÁÉÀ«µÄ¹ú¼ÊÊг¡Éú³¤Ô¶¾°¡£¡£¡£¡£¡£³ýÁËÓëÏàÖúͬ°éClinomics EuropeÅäºÏÍÆ³öColonAiQ®¼ì²âЧÀÍÍ⣬ £¬£¬£¬£¬£¬Ò²ÔÚ2024 MEDICAÊÕ»ñÁËÀ´×ÔÅ·ÖÞ¡¢À­ÃÀ¡¢Öж«¡¢¶«ÄÏÑÇµÈ¶àµØ¾­ÏúÉ̵ÄÏàÖúÒâÔ¸¡£¡£¡£¡£¡£

 

¶à²ÊÍø(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø

лл¸÷È˶Զà²ÊÍøÉúÎïµÄ¹Ø×¢ÓëÖ§³Ö£¬ £¬£¬£¬£¬£¬ÎÒÃǽ«¼ÌÐøÆð¾¢£¬ £¬£¬£¬£¬£¬ÓëÊÀ½ç¸÷µØµÄÏàÖúÆóÒµ¡¢ÙÉÐÐÃÇÅäºÏÍÆ¶¯È«ÈËÀàµÄÖ×ÁöÕï¶Ï·ÀÖÎÊÂÒµ£¬ £¬£¬£¬£¬£¬ÎªÈ«ÇòµÄÖ×Áö»¼ÕßÌṩ¸ü׼ȷ¡¢±ã½Ý¡¢¸ßÐԼ۱ȵÄÕï¶Ï½â¾ö¼Æ»®£¡In China, for the world!

 

²Î¿¼ÎÄÏ×£º

[1] Mo S. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation[J]. JAMA Oncol. 2023 Jun 1;9(6):770-778.

[2] Guo, D.-Z., et al., Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study. Clinical and Translational Medicine, 2024. 14(5): p. e1652.

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿